PNSP 29/2026 Adquisición de los principios activos Brentuximab, Vedolizumab y Fruquintinib (TAKEDA FARMACEUTICA ESPAÑA S.A.) para la GAI de Guadalajara.

different companies won its awards

38

of the awards went to the three most frequent winners

8%

of its calls state an estimated value

100%

Based on 38 awards with a named winner over the last 3 years. Counted by award, not by value, because lot and framework amounts are not comparable. Concentrated means the three most frequent winners took 65% or more of the awards; many suppliers, under 35% with at least ten different winners.

Spain · Medical equipment & pharmaceuticals

different companies won awards here

4,091

of the awards went to the three most frequent winners

4%

winners of the last 12 months were new here

3,545 of 3,800

buyers awarded contracts here

1,019

Based on 15,766 awards with a named winner over the last 3 years. Counted by award, not by value, because lot and framework amounts are not comparable. Concentrated means the three most frequent winners took 65% or more of the awards; many suppliers, under 35% with at least ten different winners. New: no award from the same buyer or market in the two years before.

Competition

tenders per lot on average (open and restricted procedures)

3.8

of those lots received a single tender

41%

of the awards went to companies based in another country

1%

of the tenders came from another country

1%

As the official award notices state them, over the last 3 years. Tenders per lot count open and restricted procedures only: in a negotiated procedure or a direct award a single tender is the procedure itself. The country is the one the notice gives for the winner.